Literature DB >> 17442446

Systemic siRNA delivery via hydrodynamic intravascular injection.

David L Lewis1, Jon A Wolff.   

Abstract

The main barrier to the use of RNAi in mammalian systems is the difficulty in delivering siRNA or shRNA to the appropriate tissues. Although progress has been made in this area, many of the technologies developed require specialized expertise and reagents that are beyond the reach of most investigators. In contrast, the hydrodynamic injection technique is simple to perform and enables highly efficient delivery of naked, unmodified siRNA to a number of tissues, especially the liver. This review describes the development of the technique and explores the possible mechanisms that enable uptake of siRNA to biological effect. Examples of the use of hydrodynamic injection in animal models of disease and for the study of gene function are presented and discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17442446     DOI: 10.1016/j.addr.2007.03.002

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  19 in total

Review 1.  Delivery of siRNA therapeutics: barriers and carriers.

Authors:  Jie Wang; Ze Lu; M Guillaume Wientjes; Jessie L-S Au
Journal:  AAPS J       Date:  2010-06-11       Impact factor: 4.009

Review 2.  Nonviral delivery of synthetic siRNAs in vivo.

Authors:  Saghir Akhtar; Ibrahim F Benter
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

Review 3.  Hepatocyte polarity.

Authors:  Aleksandr Treyer; Anne Müsch
Journal:  Compr Physiol       Date:  2013-01       Impact factor: 9.090

Review 4.  New short interfering RNA-based therapies for glomerulonephritis.

Authors:  Hideki Shimizu; Toshiro Fujita
Journal:  Nat Rev Nephrol       Date:  2011-05-24       Impact factor: 28.314

5.  siRNA Design and GalNAc-Empowered Hepatic Targeted Delivery.

Authors:  Mei Lu; Mengjie Zhang; Bo Hu; Yuanyu Huang
Journal:  Methods Mol Biol       Date:  2021

Review 6.  Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics.

Authors:  Long Xu; Thomas Anchordoquy
Journal:  J Pharm Sci       Date:  2011-01       Impact factor: 3.534

7.  Paclitaxel tumor-priming enhances siRNA delivery and transfection in 3-dimensional tumor cultures.

Authors:  Ho Lun Wong; Zancong Shen; Ze Lu; M Guillaume Wientjes; Jessie L-S Au
Journal:  Mol Pharm       Date:  2011-03-29       Impact factor: 4.939

8.  Polymeric micelles containing reversibly phospholipid-modified anti-survivin siRNA: a promising strategy to overcome drug resistance in cancer.

Authors:  G Salzano; R Riehle; G Navarro; F Perche; G De Rosa; V P Torchilin
Journal:  Cancer Lett       Date:  2013-10-04       Impact factor: 8.679

9.  In vivo inhibition of focal adhesion kinase causes insulin resistance.

Authors:  Bharti Bisht; K Srinivasan; Chinmoy S Dey
Journal:  J Physiol       Date:  2008-06-26       Impact factor: 5.182

10.  Establishment of a positive-readout reporter system for siRNAs.

Authors:  Wei-Li Liu; Douglas P Owen; Kerry D Fisher; Leonard W Seymour; Mark Stevenson
Journal:  J RNAi Gene Silencing       Date:  2009-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.